| Literature DB >> 30614185 |
Xiu Zang1, Xiangyu Meng2, Yun Wang1, Xiao Jin1, Tingting Wu1, Xuekui Liu3, Houfa Geng3, Wei Xu3, Yu Wang3, Fei Teng3, Qinqin Qiu3, Manqing Yang3, Jun Liang3.
Abstract
BACKGROUND: Pre-diabetes is considered to be an important reversible stage of type 2 diabetes (T2DM); thus, early identification of pre-diabetes may help in the prevention of T2DM. This study aimed to explore the relationship between white blood cell (WBC) counts and the cumulative risk of impaired fasting glucose (IFG) regulation at 6 years.Entities:
Keywords: fasting blood glucose; impaired fasting blood glucose regulation; risk; white blood cell count
Mesh:
Substances:
Year: 2019 PMID: 30614185 PMCID: PMC6519278 DOI: 10.1002/dmrr.3125
Source DB: PubMed Journal: Diabetes Metab Res Rev ISSN: 1520-7552 Impact factor: 4.876
Baseline characteristic of patients by quartile of white blood cell count
| White Blood Cell (109/L) | |||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 |
| |
| n | 274 | 275 | 273 | 273 | |
| Male | 109 | 111 | 108 | 108 | |
| Age, years | 47.83 ± 10.38 | 47.67 ± 10.42 | 47.94 ± 10.99 | 46.48 ± 9.74 | 0.327 |
| RBC, 109/L | 4.56 ± 0.46 | 4.63 ± 0.45 | 4.71 ± 0.43 | 4.73 ± 0.41 | <0.001 |
| HGb, g/L | 134.55 ± 17.07 | 136.78 ± 15.21 | 139.03 ± 14.02 | 140.17 ± 13.06 | <0.001 |
| PLT, 109/L | 196.08 ± 44.25 | 205.98 ± 38.92 | 216.74 ± 43.91 | 225.77 ± 42.53 | <0.001 |
| ALT, U/L | 17.54 ± 10.63 | 21.32 ± 39.39 | 19.82 ± 11.08 | 20.64 ± 12.83 | 0.211 |
| AST, U/L | 17.55 ± 5.06 | 19.60 ± 19.33 | 18.26 ± 5.42 | 18.19 ± 6.94 | 0.165 |
| TP, g/L | 75.02 ± 4.33 | 75.41 ± 3.93 | 75.89 ± 4.15 | 76.04 ± 4.59 | 0.02 |
| Scr, umol/L | 61.35 ± 13.87 | 60.18 ± 12.67 | 61.05 ± 12.34 | 60.07 ± 12.46 | 0.573 |
| SUA, umol/L | 286.94 ± 80.06 | 298.27 ± 82.90 | 305.54 ± 78.90 | 306.45 ± 73.35 | 0.015 |
| TC, mmol/L | 4.73 ± 0.88 | 4.87 ± 0.82 | 4.93 ± 0.89 | 4.95 ± 0.89 | 0.014 |
| TG, mmol/L | 1.24 ± 0.83 | 1.46 ± 1.42 | 1.55 ± 1.49 | 1.82 ± 1.64 | <0.001 |
| HDL, mmol/L | 1.59 ± 0.39 | 1.51 ± 0.37 | 1.50 ± 0.34 | 1.42 ± 0.36 | <0.001 |
| LDL, mmol/L | 2.85 ± 0.69 | 2.97 ± 0.71 | 3.01 ± 0.78 | 3.04 ± 0.76 | 0.013 |
| BMI, kg/m2 | 23.14 ± 3.08 | 23.77 ± 2.89 | 23.94 ± 3.01 | 24.53 ± 3.51 | <0.001 |
| SBP, mmHg | 122.47 ± 16.21 | 122.84 ± 15.98 | 123.35 ± 16.24 | 124.62 ± 17.69 | 0.455 |
| DBP, mmHg | 77.53 ± 10.51 | 78.13 ± 10.01 | 78.50 ± 9.99 | 79.52 ± 11.18 | 0.16 |
| FPG, mmol/L | 5.15 ± 0.39 | 5.15 ± 0.41 | 5.14 ± 0.39 | 5.16 ± 0.42 | 0.902 |
| Smoking | 30 | 33 | 42 | 51 | 0.005 |
| Drinking | 62 | 64 | 77 | 89 | 0.004 |
Abbreviations: ALT, glutamic pyruvate; AST, glutamic transaminase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting blood glucose; Hgb, haemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PLT, platelet; RBC, red blood cell; SBP, systolic pressure; Scr, serum creatinine; SUA, serum uric acid; TC, total cholesterol; TG, triglycerides; TP, total protein.
The number of patients with prediabetes in four categories of percent white blood cell (WBC) during the follow‐up period
| White Blood Cell, 109/L | |||||||
|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | χ2 |
| ||
| 1‐year follow‐up | IFG | 11 | 11 | 8 | 8 | 0.747 | 0.387 |
| Normal | 263 | 264 | 264 | 265 | |||
| 2‐year follow‐up | IFG | 23 | 18 | 17 | 20 | 0.242 | 0.622 |
| Normal | 250 | 257 | 255 | 252 | |||
| 3‐year follow‐up | IFG | 29 | 24 | 25 | 28 | 0.036 | 0.849 |
| Normal | 244 | 251 | 247 | 244 | |||
| 4‐year follow‐up | IFG | 35 | 31 | 30 | 36 | 0.017 | 0.898 |
| Normal | 237 | 244 | 242 | 234 | |||
| 5‐year follow‐up | IFG | 38 | 37 | 35 | 44 | 0.453 | 0.68 |
| Normal | 234 | 238 | 237 | 226 | |||
| 6‐year follow‐up | IFG | 40 | 45 | 43 | 60 | 4.573 | 0.032 |
| Normal | 232 | 230 | 229 | 210 | |||
Abbreviations: IFG: impaired fasting glucose; WBC: white blood cell.
Figure 1The cumulative incidence of IFG of four categories of percent WBC during follow‐up period (IFG: impaired fasting glucose; WBC: white blood cell count)
Association between baseline white blood cell (WBC) and risk of impaired fasting glucose (IFG)
| Beta | Wald |
| HR | 95% CI | |
|---|---|---|---|---|---|
| Model 1 | 0.228 | 6.015 | 0.002 | 1.187 | 1.104‐1.593 |
| Model 2 | 0.141 | 4.474 | 0.034 | 1.151 | 1.010‐1.311 |
| Model 3 | 0.086 | 4.014 | 0.042 | 1.084 | 1.001‐1.304 |
Abbreviations: HR: hazard ratio; IFG: impaired fasting glucose; WBC: white blood cell.
Model 1: unadjusted; model 2: adjusted for sex, age, and body mass index (BMI); model 3: adjusted for sex, age, BMI, systolic pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG), total cholesterol (TC), high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), serum uric acid (SUA), smoking, and drinking.
Figure 2The trend of HR with sixth of baseline WBC (HR: hazard ratio; IFG: impaired fasting glucose; WBC: white blood cells count)